CONSUMER HEALTHCARE PRODUCTS ASSOCIATION for CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 16, 2014 | $220,000 | Replaced |
| 3rd Quarter - Report | Jan 20, 2015 | $230,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
MicrobeadsH.R. 4895/S. 2902 - Microbead-Free Waters Act of 2014. Would prohibit the distribution of cosmetic products containing synthetic plastic microbeads after January 1, 2018; all sections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Alcohol and Drug Abuse ALC
DextromethorphanDextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644, all sections).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Taxation/Internal Revenue Code TAX
Flexible spending arrangements (FSA) and health savings accounts (HSA)H.R. 2835/S. 1647 - Restoring Access to Medication Act. Repeals prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections. H.R. 1248/S. 610 - Family Health Care Flexibility Act. Would also repeal prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections. Senate bill "Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act." Would renew and extend certain expired and expiring tax provisions for an additional year; all sections. Companion legislation not yet introduced in House.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Chemicals/Chemical Industry CHM
Toxic Substances Control Act of 1976 (P.L. 94-469)S. 1009 - Chemical Safety Improvement Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections. Potential House bill - Chemicals in Commerce Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections (no bill number).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Food Industry (safety, labeling, etc.) FOO
Dietary SupplementsS. 1425 - Dietary Supplement Labeling Act. Expands registration requirements for dietary supplement manufacturing or processing facilities; requires development of a definition of "conventional food," including foods marketed as dietary supplements; all sections. H.R. 4771/S. 2012 - Designer Anabolic Steroid Control Act (DASCA). Food and Drug Administration (FDA) regulation of anabolic steroids; all sections. Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues."
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Pharmacy PHA
Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R. 4250/S. 2141 - Sunscreen Innovation Act. Would require FDA to approve or deny new sunscreen ingredient applications under the "time and extent" application (TEA) process within a certain timeframe after submission; all sections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.